Interview with Jacques Servier, Founder, Servier France
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Address: 22, Rue Garnier 92200 Neuilly sur Seine,France
Tel: +33 (0)1 55 72 60 00
Our entire activity is based on three key principles:
• Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
• Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
• Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
Figures
• Leading French independent pharmaceutical company
• Second French pharmaceutical company worldwide
• SERVIER is established in 140 countries
• 85% of SERVIER’s sales are achieved internationally
• Consolidated turnover for the 2007/2008 financial year: €3.7 billion
• More than 25% of SERVIER’s turnover is invested in Research and Development
• Worldwide workforce of over 20 000, including nearly 3 000 in Research and Development
• SERVIER contributes 29% of the trade surplus of France’s pharmaceutical industry
Osteoporosis
Diabetes
Cardiovascular
Venous Diseases
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to…
Franck Puget, managing director for CSL Behring in France, discusses the blood plasma specialist’s commitment to France, building bridges with public authorities, and regulatory attitudes towards rare disease treatments. …
Guillaume El Glaoui, co-founder and CEO of Laboratoires Majorelle, discusses what spurred the creation of the company, its success of gaining the first reimbursement ever of a condom in France,…
Eric Goupil, CEO of Unither Pharmaceuticals, discusses the company’s development strategy moving forward after the completion of a leveraged buyout in 2017. Additionally, Goupil shares the CDMO’s innovation capabilities as…
Mathilde Lignot-Leloup, director of the French Social Security, provides a fascinating look into the French social system and speaks about its ongoing transformation. She elaborates on change management processes within…
Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also…
Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access…
Guy Maugis, president of the Franco-German Chamber of Commerce and Industry, explains the impact of the Macron government on the attractiveness of France as well as the importance of a…
Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to…
Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to…
In this exclusive interview, David Loew, executive vice president of Sanofi Pasteur, discusses the future of vaccines in France and the rest of the world, their strategic role in reducing…
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
See our Cookie Privacy Policy Here
